Alzheimer's disease (AD) is the most common cause of late-life dementia. Characterized by progressive neurodegeneration, the disease is expressed as gradual memory loss together with decline in cognitive abilities and other brain functions. Despite extensive research over the past decade, the cause and cure of AD both remain largely unknown. Several AD-associated deficits have been targeted for interventions, including those based on amyloid-beta, tau, and inflammation hypotheses. 11
Over the last 3 decades, b-amyloid has been the centre of a great deal of clinical trials for new drug development, but to date, none have proven successful. 8, 12 Drug development has also targeted the Tau pathology with unproven effect. 12, 13 Approaches that have proven successful for the treatment of the symptoms of AD and amnestic mild cognitive impairment (MCI) have targeted the cholinergic system to slow down regression. 14 The US Food and Drug Administration (FDA) approved medications include 3 cholinesterase inhibitors (ChEIs: donepezil, galantamine, and rivastigmine), memantine (that targets the glutamatergic system), and a combined treatment of ChEI and memantine. [15] [16] [17] Based on the cholinergic hypothesis, AD is associated with reduced synthesis of the neurotransmitter acetylcholine (a neurotransmitter involved in memory, attention, arousal, and motivation)
in the basal forebrain. 14 During synaptic transmission, acetylcholine is released into the synaptic cleft to activate receptors on the postsynaptic neurons. After transmission, acetylcholinesterase breaks down acetylcholine, so it can be reused by the presynaptic neuron.
AD damages the cholinergic neurons, thereby reducing the amount of acetylcholine in the system. A ChEI slows down the loss of acetylcholine by blocking the activity of acetylcholinesterase, helping compensate for the damage of brain cells. 18 The other type of current AD medication, memantine, acts as a NMDA (N-methyl-D-aspartate) receptor antagonist on the glutamatergic system, blocking NMDA glutamate receptors to prevent overstimulation from excessive glutamate synthesis. While ChEIs are typically used in treating early AD and MCI symptoms, memantine is used to treat moderate-to-severe symptoms of AD. 19, 20 Advances of functional magnetic resonance imaging (MRI) technologies have been used to understand medication effect on AD treatment. Blood oxygen level-dependent functional MRI (BOLDfMRI) maps hemodynamic responses to neural activity, 21, 22 based on the paramagnetic differences between oxygenated and deoxygenated hemoglobin, which allows the detection of activated brain areas as their oxygen demand increases. 21, 22 BOLD-fMRI can be divided into 2 categories: task phase and resting phase. The former uses relative changes of BOLD signal intensity from baseline when performing a task or handling a stimulus, to infer brain areas that are activated. 23 The latter measures spontaneous low-frequency fluctuations in the BOLD signal without an explicit task to investigate the status of brain functional connection. 24 Resting-phase fMRI can be particularly useful in patients who are not able to do fMRI tasks because they are limited by their disease condition, for example, AD. 25 Perfusion-weighted imaging (PWI) represents another important functional MRI modality. PWI is used for noninvasively assessing cerebral hemodynamics (cerebral blood flow [CBF] and volume), 26 which traditionally has relied on technologies that require use of a tracer that releases ionizing radiation. CBF is the volume of blood flowing through a mass of brain tissue over a certain period of time (reported as mL/100 g/min). 26, 27 PWI can be divided into dynamic perfusion imaging, which requires exogenous contrast tracers (eg, dynamic contrast enhancement imaging or dynamic susceptibility contrast), and arterial spin labeling which does not require exogenous contrast tracers, 28 in which radio frequency pulses are optimized to label inflowing blood water, allowing the measurement of arterial blood flow. 29 The latter technique is completely noninvasive and can be used to map brain activity, making it the preferable PWI method.
The in vivo proton magnetic resonance spectroscopic (MRS) had also gained some popularity in AD research. 30 Based on the magnetic resonance properties of the hydrogen proton, MRS can be used to quantify levels of neurometabolites in the living brain. 23, 31, 32 When excited in the magnetic field, each hydrogen nucleus inside a metabolite goes through a tiny shift in resonant frequency (ie, chemical shift), expressed in parts per million (ppm). Depending on factors in the chemical environment (eg, atom negativity, electron density, magnetic field strength), an MRS signal is generated. MRS acquisition can either be in localized brain regions (ie, single-voxel MRS) or as chemical shift imaging (MRSI). The most commonly studied brain metabolites are N-acetyl aspartate (NAA), creatine (Cr), choline (Cho),
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Here, we review current findings and discuss the future role of these functional MRI modalities, for example, BOLD-fMRI, PWI, and MRS, in studying the treatment effects of various medications on AD and MCI. For this purpose, we surveyed the literature and summarized the information. Our focus is the medications that have been approved by FDA to treat AD and MCI (ie, ChEIs and memantine), rather than trials for developing new drugs. Studies that reported use of other on-shelf medications primarily for treating other conditions (eg, epilepsy, diabetes) on AD-associated comorbidities were also briefly discussed.
2 | ME TH ODS
| Search terms
We searched MEDLINE, which represents the most well-known biomedical research database, with comprehensive coverage of biomedical publications of more than 5600 journals. 36 During the initial search, we used terms that combined the following 3 sets of phrases or key words. Set-1: "Alzheimer's" or "AD" or "mild cognitive impairment" or "MCI" or "dementia". Set-2: "therapeutic" or "therapy" or "medication" or "treatment" or "pharmacological" or "memantine" or "donepezil" or "galantamine" or "rivastigmine"
or "cholinesterase inhibitors" or "cholinesterase inhibition" or "ChEI"
or "cholinergic". Set-3: "functional MRI" or "fMRI" or "functional magnetic resonance imaging" or "BOLD" or "cortical activation" or "functional connectivity" or "MRS" or "MRS imaging" or "Magnetic resonance spectroscopy" or "MR spectroscopy" or "perfusion MRI"
or "Perfusion Weighted Imaging" or "PWI" or "Cerebral Blood Flow" or "CBF" or "Cerebral Blood Volume" or "CBV" or "Hemodynamic."
This initial search yielded 1796 articles ( Figure 1 ).
| Inclusion and exclusion criteria
Articles were further eliminated by restricting inclusion to studies that investigated human subjects, were published in the English language, and had a full-text, using Set-4: "Humans" and Set-5: "English," and a subset of 1084 articles was resulted. After such compilation, review and opinion papers were further discarded.
Through title and abstract review of articles that reported original research studies, those that used only non-MR imaging techniques such as single-photon emission computed tomography, positron emission tomography, electroencephalography, and magnetoencephalography, and those that used nonpharmacological treatments such as acupuncture or cognitive training were further discarded. To ensure a complete inclusion, a consultation of other reviews was conducted, for example, for BOLD-fMRI. 37 These processes yielded a final subset of 55 articles remaining to be further reviewed (Figure 1) , arranged based on the functional MRI methods used, that is, BOLD (n = 38), PWI (n = 4), and MRS (n = 14).
3 | RESULTS
| BOLD-fMRI studies
Studies investigating the effects of pharmacological treatments in AD and MCI using BOLD-fMRI were summarized in Tables 1-3, with individual studies described in Table 1 .
Rombouts et al 38 reported the first fMRI study on AD treatment in human subjects. Patients with mild AD performed face-encoding and n-back tasks. An increase in fMRI activation in the fusiform gyrus and frontal cortices was found with a single-dose rivastigmine administration. 38 The same group 39 scanned 28 MCI patients at baseline, after a single dose of galantamine, and after 5 days of galantamine treatments. An increased activation was found during face-encoding task after 5 days in the anterior cingulate, left prefrontal, and occipital gyri, and in the posterior hippocampus, while during the working memory task there was increased fMRI activation in the right precuneus and right middle frontal gyrus. 39 Goekoop et al 40 Shanks et al 44 reported that in AD, galantamine increased fMRI activation in the left inferior, middle, and medial frontal, and parahippocampal gyri during a semantic association task, and in the bilateral cingulate gyrus during a target detection task. In their subsequent study, McGeown et al 45 used rivastigmine and reported an increased fMRI activation in the bilateral middle frontal, paracentral, parahippocampal, and fusiform gyri during a semantic association task, and in the right frontal and right precentral gyri during a working memory task. Decreased activation was found in the left middle frontal, precentral, and cingulate gyri, insula, and thalamus during the working memory task. 45 Later, McGeown et al, 46 evaluated the effects of 20-week donepezil treatment applying the same fMRI tasks, but found decreased fMRI activation, whereas increased deactivation was found in task-irrelevant areas. 45, 46 In a retrospective analysis, Venneri et al 47 divided the patients into drug responders and nonresponders and observed activation changes only in the former group. the inferior frontal junction during a delayed memory recognition task. Dhanjal et al studied mild AD, MCI, and health control (HC) using auditory encoding 60 and retrieval 61 and showed that donepezil was effective in AD with an increased fMRI activation in the left anterior ventral temporal cortex and pars triangularis during encoding, 60 and in the left lateral posterior parietal cortex and lateral frontal cortex during retrieval. 61 Risacher et al 62 Another resting-state study by Li et al 67 used both BOLD and PWI fMRI and reported increased network connectivity in the parahippocampal, temporal, parietal and prefrontal cortices in AD after 12-week donepezil treatment, and changes in functional connectivity and regional CBF in the medial prefrontal lobe were correlated.
| Perfusion-weighted imaging (PWI) studies
There have been only a small number of PWI studies investigating the effects of pharmacological treatments in AD and MCI. These were summarized in Tables 4 and 5 , with individual studies described in Table 4 .
The study by Li et al 67 used pseudo-continuous arterial spin labeling-PWI (PCASL-PWI), based on the arterial spin labeling technique, and found an enhancement of the regional CBF in the middle and posterior cingulate cortex in AD after donepezil treatment (also see above with BOLD-fMRI). 67 Chaudhary et al 68 reported ChEI treatment-elicited increases in CBF in the lateral temporal lobe, posterior and anterior cingulate gyrus (including white matter), and prefrontal regions, independent of the regional volume of brain tissues.
A subsequent study by Janik et al 69 significantly lower CBF and BOLD signal intensity than HC. After 6 months of ChEI treatment, a further CBF decline was seen in the occipital lobe during visual stimulation, whereas the CBF response was stabilized after 12 months of treatment. 69 
| Proton MRS and MRS imaging studies
Studies investigating the effects of pharmacological treatments in AD and MCI using proton MRS or MRS imaging were summarized in Tables 6 and 7 , with individual studies described in Table 6 . GUO ET AL.
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A few studies showed changes in glutamate rather than NAA.
Glodzik et al 79 investigated memantine effect on AD, MCI, and younger and older HC subjects using MRS imaging, and reported a significantly reduced rate of Glu/Cr increase in the left hippocampus in the treated subjects, compared to nontreated subjects; a change in Glu/Cr was not found in the right hippocampus, nor in NAA/Cr on either side. 79 Bartha et al 80 conducted a MRS study at 4.0T and reported a decrease in the level of NAA, Cho, and mI/Cr in the right hippocampal VOI in AD after donepezil treatment; however, the level of Glu remained relatively stable over the 16-week treatment duration, which was interpreted as a positive medication effect. 80 The same group 81 further tested the effect of galantamine in treating AD, and were able to identify an increase in Glu in the right hippocampal VOI, following 4-month treatment, while a change in NAA was not found. (Table 7 ; Figures 2C and 3C ). Among the 3 ChEIs with a name reported in the original studies, donepezil was studied more.
Memantine was typically studied using MRS (Figure 3 ), related to its role on moderate AD.
| Effect of AD medications on brain functional activation
The BOLD-fMRI studies under review used the same EPI-echo planar imaging sequence, 23 but were conducted under different treatment conditions (eg, medication, dosage, duration) and experimental designs (eg, tasks).
The resting-phase studies consistently suggested that each treatment resulted in increased activation in multiple brain regions (posterior cingulate cortex, parahippocampus, dorsolateral frontal cortex, middle cingulate, precuneus, anterior hippocampus, middle frontal, and precentral gyri, insular cortex and the thalamus) and increased functional connectivity in multiple networks (eg, the default mode, dorsal attention, control and salience networks), 52, 54, [63] [64] [65] [66] [67] and that the brain functional responses were often correlated with cognition. 52, 66, 67 The task-phase studies revealed different patterns of brain activation post-treatment, often depending on the fMRI tasks being used (Table 3) . Visual working memory tasks increased activation in the bilateral inferior, middle, and superior frontal gyrus, and right precuneus; 38, 39, 45, 47 auditory working memory tasks increased activation of the anterior ventral temporal cortex, pars triangularis, and left hippocampus, 60, 61 while these also included the left dorsolateral prefrontal cortex and superior frontal cortex. 41 Face recognition task was associated with an increase in the bilateral prefrontal cortex, left fusiform, left posterior cingulate cortex, bilateral temporal lobes, left parietal lobe, and right parahippocampus. 40, 48, 55, 59 Semantic association task was associated with variable results in several brain regions.
44-47
The 2 studies on memantine and combined ChEI and memantine treatments both suggested a positive effect.
53,58
| Effect of AD medications on brain circulation
The PWI studies under review all used PCASL. [67] [68] [69] The studies consistently suggested a treatment-induced positive effect: a CBF increase in multiple brain regions (lateral temporal lobe, cingulate, A, Blood oxygen level-dependent fMRI (BOLD-fMRI); B, perfusion-weighted imaging (PWI); C, proton magnetic resonance spectroscopy (MRS) and MRS imaging. ChEI, cholinesterase inhibitors; *Can be a ChEI of any type (ie, the original studies did not report the exact name); other medications: physostigmine (n = 2), levetiracetam (n = 2), caffeine (n = 1), Chinese herbal medicine (n = 3), xanomeline (n = 2), or metformin (n = 1) and the white matter of posterior cingulate and prefrontal) that was clinically meaningful 67, 68 or CBF stabilization. 69 
| Effect of AD medications on brain metabolites
The MRS studies under review used several popular sequences for VOI selection, for example, PRESS and LASER. 30 They all examined changes in NAA (surrogate neuronal marker) in response to treatment, while high-field studies also examined Glu (excitatory neurotransmitter and involvement in glucose metabolism).
Magnetic resonance spectroscopic findings have varied markedly, presumably related to the differences in medication and treatment duration being applied, and brain location being examined. Most studies suggested a positive ChEI treatment effect based on increased NAA or NAA/Cr in the posterior cingulate gyrus, hippocampus, and prefrontal lobe; [70] [71] [72] [73] [74] 81 some also suggested a change of Im/Cr in the occipital and prefrontal lobe. 72, 73 A small number of studies showed decreased NAA in the hippocampus, posterior cingulate gyrus, or dorsolateral prefrontal cortex. 76, 78, 80 A few studies suggested a positive treatment effect based on the change of Glu or Glu/Cr in the hippocampus, 81 while other studies failed to show such a change. 76, 80 Several studies suggested the clinical meaningfulness of the brain metabolite changes.
71-73,81
Studies have not suggested a significant change in the level of NAA/Cr or Glu/Cr post memantine treatment, 73, 75, 79 likely reflecting a disease-condition influence, while the efficacy of combining ChEImemantine was also unclear. Using BOLD-fMRI, Bentley et al 87, 88 showed that single-dose physostigmine modulated AD patients' visual and attentional responses and help with memory. Bakker et al 89, 90 showed that levetiracetam helped reduce hippocampal hyperactivity and improve medial temporal lobe network in MCI. Haller et al 91 reported that caffeine administration enhanced brain response in MCI. Zhang et al [92] [93] [94] reported the effect of Chinese medicine in treating MCI at both resting and task phases.
Using MRS, Satlin et al 85 showed decreased Cho/Cr in parietal lobe, while Frederick et al 86 showed improved acetylcholine synthesis, with xanomeline treatment.
Using PCASL-PWI, Koenig et al 84 showed an orbitofrontal cerebral blood flow increase in MCI and AD with metformin treatment. However, interpretation of task-based data can be limited by the choice of experimental paradigm. Ability to attend to task can also bias resulting activation. Even so, data acquisition with BOLD-fMRI, PWI, and MRS can also be completed without a task performance, particularly beneficial in the study of AD.
Another caveat of functional MRI is related to unsatisfactory signal-to-noise ratio with functional imaging data, which can affect the complexity of data processing and accuracy of analysis results, especially regarding quantification. With this aspect, high MRI field strengths have great advantages.
In addition, caution should be taken to result interpretation by taking into account details in the study design. Even when using the same imaging technologies, variations can occur in field strength, medication dose, treatment duration, sample size, and analysis methods, leading to possible variability in the result.
In the future, multiple modalities of functional MRI technology can be combined to integrate different aspects of brain responses, allowing us to achieve a more comprehensive interpretation of the pharmacological effects of treatment on AD.
| CONCLUSION
Functional MRI techniques have provided valuable information over the past few decades, in helping researchers and neuroscientists understand the treatment effect of AD medications. This information is critical to developing patient-centered novel/better approaches that aim to potentially prevent and cure the disease.
